• Something wrong with this record ?

Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

O. Landgren, K. Weisel, L. Rosinol, C. Touzeau, M. Turgut, R. Hajek, P. Mollee, JS. Kim, N. Shu, X. Hu, C. Li, SZ. Usmani

. 2022 ; 198 (6) : 988-993. [pub] 20220524

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural

Persistent link   https://www.medvik.cz/link/bmc22024524

Grant support
P30 CA240139 NCI NIH HHS - United States

CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024524
003      
CZ-PrNML
005      
20221031100109.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.18233 $2 doi
035    __
$a (PubMed)35608261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Landgren, Ola $u Division of Hematology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA $1 https://orcid.org/0000000164854839
245    10
$a Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study / $c O. Landgren, K. Weisel, L. Rosinol, C. Touzeau, M. Turgut, R. Hajek, P. Mollee, JS. Kim, N. Shu, X. Hu, C. Li, SZ. Usmani
520    9_
$a CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.
650    _2
$a dospělí $7 D000328
650    12
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a cytogenetické vyšetření $7 D020732
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $x genetika $7 D009101
650    _2
$a prognóza $7 D011379
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Weisel, Katja $u Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Rosinol, Laura $u Hospital Clínic, IDIBAPS, Barcelona, Spain $1 https://orcid.org/0000000225349239
700    1_
$a Touzeau, Cyrille $u Service d'hématologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France $1 https://orcid.org/0000000302752575
700    1_
$a Turgut, Mehmet $u Department of Internal Medicine, Division of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey
700    1_
$a Hajek, Roman $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267
700    1_
$a Mollee, Peter $u Department of Haematology, Princess Alexandra Hospital and University of Queensland Medical School, Brisbane, QLD, Australia
700    1_
$a Kim, Jin Seok $u Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of South Korea $1 https://orcid.org/0000000189868436
700    1_
$a Shu, Natalie $u Parexel, Chengdu, China
700    1_
$a Hu, Xuguang $u Amgen Inc., Thousand Oaks, California, USA
700    1_
$a Li, Chuang $u Amgen Inc., Thousand Oaks, California, USA
700    1_
$a Usmani, Saad Z $u Memorial Sloan Kettering Cancer Center, New York, New York, USA
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 198, č. 6 (2022), s. 988-993
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35608261 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100107 $b ABA008
999    __
$a ok $b bmc $g 1854316 $s 1175814
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 198 $c 6 $d 988-993 $e 20220524 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$a P30 CA240139 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options